CRISPR Therapeutics
CRSP
CRSP
471 hedge funds and large institutions have $4.52B invested in CRISPR Therapeutics in 2021 Q3 according to their latest regulatory filings, with 58 funds opening new positions, 193 increasing their positions, 117 reducing their positions, and 79 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
27% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 79
31% less capital invested
Capital invested by funds: $6.57B → $4.52B (-$2.05B)
83% less funds holding in top 10
Funds holding in top 10: 12 → 2 (-10)
Holders
471
Holding in Top 10
2
Calls
$294M
Puts
$392M
Top Buyers
| 1 | +$28.8M | |
| 2 | +$28.6M | |
| 3 | +$28.1M | |
| 4 |
AC
Armistice Capital
New York
|
+$24.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$19.6M |
Top Sellers
| 1 | -$76.6M | |
| 2 | -$47.6M | |
| 3 | -$46.3M | |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$21.3M |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$19.6M |